Company intelligence / Profile preview
Sulfateq BV
Groningen, Groningen, Netherlandssulfateqbv.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SUL-238 is currently in Phase I clinical trials in collaboration with Turkish partner GEN Ilac. It is reported to lead to persisting improvement of vascular aging. SUL-138 has shown high efficacy for protection against cooling-rewarming damage in pre-clinical testing for acute and chronic kidney disease.
- Therapeutic areas
- PulmonologyCardiovascularNephrology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
GEN Ilac
Beyond the preview
Go deeper on Sulfateq BV.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sulfateq BV.